



# Drug and Biologic Coverage Policy

Effective Date ..... 4/01/2026  
Coverage Policy Number ..... 5026

## Immune Globulin

### Table of Contents

Overview ..... 1  
 Medical Necessity Criteria ..... 2  
 Reauthorization Criteria ..... 12  
 Authorization Duration ..... 12  
 Conditions Not Covered ..... 12  
 Coding Information ..... 12  
 Background ..... 13  
 References ..... 20  
 Revision Details ..... 24

### Related Coverage Resources

#### INSTRUCTIONS FOR USE

The following Coverage Policy applies to health benefit plans administered by Cigna Companies. Certain Cigna Companies and/or lines of business only provide utilization review services to clients and do not make coverage determinations. References to standard benefit plan language and coverage determinations do not apply to those clients. Coverage Policies are intended to provide guidance in interpreting certain standard benefit plans administered by Cigna Companies. Please note, the terms of a customer's particular benefit plan document [Group Service Agreement, Evidence of Coverage, Certificate of Coverage, Summary Plan Description (SPD) or similar plan document] may differ significantly from the standard benefit plans upon which these Coverage Policies are based. For example, a customer's benefit plan document may contain a specific exclusion related to a topic addressed in a Coverage Policy. In the event of a conflict, a customer's benefit plan document always supersedes the information in the Coverage Policies. In the absence of a controlling federal or state coverage mandate, benefits are ultimately determined by the terms of the applicable benefit plan document. Coverage determinations in each specific instance require consideration of 1) the terms of the applicable benefit plan document in effect on the date of service; 2) any applicable laws/regulations; 3) any relevant collateral source materials including Coverage Policies and; 4) the specific facts of the particular situation. Each coverage request should be reviewed on its own merits. Medical directors are expected to exercise clinical judgment where appropriate and have discretion in making individual coverage determinations. Where coverage for care or services does not depend on specific circumstances, reimbursement will only be provided if a requested service(s) is submitted in accordance with the relevant criteria outlined in the applicable Coverage Policy, including covered diagnosis and/or procedure code(s). Reimbursement is not allowed for services when billed for conditions or diagnoses that are not covered under this Coverage Policy (see "Coding Information" below). When billing, providers must use the most appropriate codes as of the effective date of the submission. Claims submitted for services that are not accompanied by covered code(s) under the applicable Coverage Policy will be denied as not covered. Coverage Policies relate exclusively to the administration of health benefit plans. Coverage Policies are not recommendations for treatment and should never be used as treatment guidelines. In certain markets, delegated vendor guidelines may be used to support medical necessity and other coverage determinations.

### Overview

This policy supports medical necessity review for the following intravenous immune globulin (IVIG) and subcutaneous immune globulin (SCIG) products:

- Alyglo™ (immune globulin intravenous solution-stwk – GC Biopharma)
- Asceniv™ (immune globulin intravenous liquid-sira)
- Bivigam® (immune globulin intravenous)
- Cutaquig® (immune globulin subcutaneous 16.5% solution)
- Cuvitru™ (immune globulin subcutaneous 20% solution)
- Flebogamma® DIF (immune globulin intravenous)
- Gammagard Liquid, Gammagard® S/D < 1 mcg/mL in 5% solution (immune globulin infusion)

- Gammaked™ (immune globulin injection caprylate/chromatography purified)
- Gammaplex® (immune globulin intravenous)
- Gamunex®-C (immune globulin injection caprylate/chromatography purified)
- Hizentra® (immune globulin subcutaneous 20% liquid)
- HyQvia (immune globulin infusion 10% with recombinant human hyaluronidase)
- Octagam® (immune globulin intravenous)
- Panzyga® (immune globulin intravenous-ifas)
- Privigen® Liquid (immune globulin intravenous)
- Xembify® (immune globulin subcutaneous 20% solution)
- Yimmugo® (immune globulin intravenous solution-dira – Biotest (Grifols))

Additional criteria that support the review for medical necessity exceptions of non-covered products are located in the [Non-Covered Product Table](#) by the respective plan type and drug list where applicable.

Intravenous immunoglobulins (IVIG) for COVID-19 uses is addressed in a separate coverage policy. Please refer to the related coverage policy link above (COVID-19: Drug and Biologic Therapeutics).

## Medical Necessity Criteria

Immune globulin products are considered medically necessary when **BOTH** of the following are met:

1. Individual meets the [Specific Medical Necessity Criteria by Condition](#) (follow the below links to the related criteria section)
  - I. [Primary Immunodeficiency Disorder \(PID\)](#)
  - II. [Secondary Immunodeficiency](#)
  - III. [Infectious Disease](#)
  - IV. [Transplantation](#)
  - V. [Hematology](#)
  - VI. [Neurology](#)
  - VII. [Rheumatology](#)
  - VIII. [Dermatology](#)
2. Non-Covered Product Criteria is met, refer to below table

### Employer Group and Individual and Family Plan Non-Covered Products and Criteria:

Non-Covered Product	Criteria
<b>Alyglo</b> (immune globulin intravenous, human-stwk, 10% solution)	Patient meets <b>ONE</b> of the following (A or B): A. Patient has tried <b>THREE</b> of the following products (i, ii, iii, iv, v, vi, vii, viii, ix): i. Bivigam ii. Flebogamma DIF iii. Gammagard Liquid iv. Gammaked v. Gammaplex vi. Gamunex-C vii. Octagam viii. Panzyga ix. Privigen B. According to the prescriber, a product with minimal content of coagulation factor XIa is needed based on a comorbidity of the patient.
<b>Asceniv</b>	Patient meets <b>ONE</b> of the following (A or B):

Non-Covered Product	Criteria
(immune globulin intravenous ,human -sira, 10% liquid)	<p>A. Patient has tried <b>THREE</b> of the following products (i, ii, iii, iv, v, vi, vii, viii, ix)::</p> <ol style="list-style-type: none"> <li>i. Bivigam</li> <li>ii. Flebogamma DIF</li> <li>iii. Gammagard Liquid</li> <li>iv. Gammaked</li> <li>v. Gammaplex</li> <li>vi. Gamunex-C</li> <li>vii. Octagam</li> <li>viii. Panzyga</li> <li>ix. Privigen</li> </ol> <p>B. According to the prescribing physician, the patient requires an immune globulin product with elevated levels of respiratory syncytial virus (RSV) antibodies (e.g., if the patient has repeated RSV infections despite adequate IVIG dosing in a compliant patient)</p>
<b>Gammagard S/D IgA ≤ 1 mcg/mL</b> (immune globulin intravenous [IVIG])	<p>Patient meets <b>ONE</b> of the following (A or B):</p> <p>A. Patient has tried <b>THREE</b> of the following products (i, ii, iii, iv, v, vi, vii, viii, ix):</p> <ol style="list-style-type: none"> <li>i. Bivigam</li> <li>ii. Flebogamma DIF</li> <li>iii. Gammagard Liquid</li> <li>iv. Gammaked</li> <li>v. Gammaplex</li> <li>vi. Gamunex-C</li> <li>vii. Octagam</li> <li>viii. Panzyga</li> <li>ix. Privigen</li> </ol> <p>B. Patient requires an IVIG product with the lowest IgA content</p>
<b>Yimmugo</b> (immune globulin intravenous, human-dira, 10% liquid)	<p>Patient has tried <b>THREE</b> of the following products (i, ii, iii, iv, v, vi, vii, viii, ix):</p> <ol style="list-style-type: none"> <li>i. Bivigam</li> <li>ii. Flebogamma DIF</li> <li>iii. Gammagard Liquid</li> <li>iv. Gammaked</li> <li>v. Gammaplex</li> <li>vi. Gamunex-C</li> <li>vii. Octagam</li> <li>viii. Panzyga</li> <li>ix. Privigen</li> </ol>

**Specific Medical Necessity Criteria by Condition:**

**I. Primary Immunodeficiency Disorder (PID)**

Condition	Criteria for Use
<b>Hypogammaglobulinemia (including Common Variable Immunodeficiency [CVID])</b>	<p><b>ALL of the following are met:</b></p> <ul style="list-style-type: none"> <li>• <b>Immunologic evaluation including</b> documented serum IgG below the lower limits of normal of the laboratory's reported value on at least two occasions</li> <li>• <b>Impaired Antibody Response (EITHER of the following):</b></li> </ul>

	<ul style="list-style-type: none"> <li>○ Lack of protective antibody titers (tetanus and diphtheria or HiB) measured 3–4 weeks after immunization</li> <li>○ Inadequate responsiveness to pneumococcal polysaccharide vaccine (Pneumovax® 23) 4–8 weeks after vaccination as defined by <b>EITHER</b> of the following: <ul style="list-style-type: none"> <li>▪ Age &lt; 6 years, &lt; 50% of serotypes are protective (≥ 1.3 mcg/mL per serotype)</li> <li>▪ Age ≥ 6 years, &lt; 70% of serotypes are protective (≥ 1.3 mcg/mL per serotype)</li> </ul> </li> <li>● <b>Recurrent Infection (ALL of the following):</b> <ul style="list-style-type: none"> <li>○ History of recurrent bacterial sinopulmonary infections requiring multiple courses or prolonged antibiotic therapy</li> <li>○ Evidence of management of underlying conditions such as asthma or allergic rhinitis that may predispose to recurrent infections where applicable</li> <li>○ Supporting diagnostic imaging and/or laboratory results where applicable</li> </ul> </li> </ul>
<b>IgG Subclass Deficiency</b>	<p><b>ALL of the following are met:</b></p> <ul style="list-style-type: none"> <li>● <b>Immunologic evaluation</b> including documented normal total serum IgG with one or more subclasses, excluding isolated subclass IgG4, below the lower limits of normal of the laboratory’s reported value on at least two occasions</li> <li>● <b>Impaired Antibody Response</b> – Inadequate responsiveness to pneumococcal polysaccharide vaccine (Pneumovax® 23) 4–8 weeks after vaccination as defined by <b>EITHER</b> of the following: <ul style="list-style-type: none"> <li>○ Age &lt; 6 years, &lt; 50% of serotypes are protective (≥ 1.3 mcg/mL per serotype)</li> <li>○ Age ≥ 6 years, &lt; 70% of serotypes are protective (≥ 1.3 mcg/mL per serotype)</li> </ul> </li> <li>● <b>Recurrent Infection (ALL of the following)</b> <ul style="list-style-type: none"> <li>○ History of recurrent bacterial sinopulmonary infections requiring multiple courses or prolonged antibiotic therapy</li> <li>○ Evidence of management of underlying conditions such as asthma or allergic rhinitis that may predispose to recurrent infections where applicable</li> <li>○ Supporting diagnostic imaging and/or laboratory results where applicable</li> </ul> </li> </ul>
<b>Selected Specific Primary Immunodeficiency Disorders</b>	<p><b>ONE of the following criteria is met:</b></p> <ul style="list-style-type: none"> <li>● Agammaglobulinemia defined as serum IgG &lt; 200 mg/dl</li> <li>● Extremely low (&lt; 2%) or absent B cell count (CD19+)</li> <li>● Documentation of a recognized genetic defect supporting diagnosis (see <a href="#">Appendix 1</a>, <a href="#">Appendix 2</a>, and <a href="#">Appendix 3</a>)</li> <li>● Transient hypogammaglobulinemia of infancy with serum immunoglobulins below the age-specific normal range and <b>BOTH</b> of the following: <ul style="list-style-type: none"> <li>○ Evidence of recurrent bacterial sinopulmonary infections requiring antibiotic therapy (IVIG is only used for up to six months before re-evaluating the need for continued treatment)</li> <li>○ Inadequate responsiveness to pneumococcal polysaccharide vaccine (Pneumovax® 23) 4–8 weeks after vaccination defined as &lt; 50% of serotypes are protective (≥ 1.3 mcg/mL per serotype)</li> </ul> </li> <li>● Hyperimmunoglobulinemia E syndrome as evidenced by: <ul style="list-style-type: none"> <li>○ Elevated serum IgE level, the presence of staphylococcus-binding IgE, eosinophilia, and recurrent lung and/or skin infections (abscess, chronic eczematous dermatitis) <b>AND</b></li> <li>○ Impaired Antibody Response (<b>EITHER</b> of the following):</li> </ul> </li> </ul>

	<ul style="list-style-type: none"> <li>▪ Lack of protective antibody titers (tetanus and diphtheria or HiB) measured 3–4 weeks after immunization</li> <li>▪ Inadequate responsiveness to pneumococcal polysaccharide vaccine (Pneumovax® 23) 4–8 weeks after vaccination as defined by <b>EITHER</b> of the following: <ul style="list-style-type: none"> <li>• Age &lt; 6 years, &lt; 50% of serotypes are protective (≥ 1.3 mcg/mL per serotype)</li> <li>• Age ≥ 6 years, &lt; 70% of serotypes are protective (≥ 1.3 mcg/mL per serotype)</li> </ul> </li> </ul>
<b>Specific Antibody Deficiency (SAD)</b>	<p><b>ALL of the following criteria are met:</b></p> <ul style="list-style-type: none"> <li>• <b>Immunological evaluation</b> including documented normal serum IgG, IgG subclass, IgA, and IgM</li> <li>• Normal responses to protein antigens (tetanus and diphtheria toxoid) measured 3-4 weeks after immunization</li> <li>• <b>Inadequate responsiveness</b> to pneumococcal polysaccharide vaccine (Pneumovax® 23) 4–8 weeks after vaccination as defined by <b>EITHER</b> of the following: <ul style="list-style-type: none"> <li>○ Age &lt; 6 years, &lt; 50% of serotypes are protective (≥ 1.3 mcg/mL per serotype)</li> <li>○ Age ≥ 6 years, &lt; 70% of serotypes are protective (≥ 1.3 mcg/mL per serotype)</li> </ul> </li> <li>• <b>Recurrent Infection (ALL of the following):</b> <ul style="list-style-type: none"> <li>○ History of severe and recurrent bacterial sinopulmonary infections despite documentation of both: <ul style="list-style-type: none"> <li>▪ Prevnar 7 or Prevnar 13 vaccination</li> <li>▪ Documented failure/inadequate response, contraindication, or intolerance to the use of prophylactic antibiotic therapy</li> </ul> </li> <li>○ Evidence of management of underlying conditions such as asthma or allergic rhinitis that may predispose to recurrent infections where applicable</li> <li>○ Supporting diagnostic imaging and/or laboratory results where applicable</li> </ul> </li> </ul>

## II. Secondary Immunodeficiency

Condition	Criteria for Use
<b>Acquired Immunosuppression</b>	<p>Prevention of infection in individuals meeting <b>ALL</b> of the following:</p> <ul style="list-style-type: none"> <li>• Presence of hypogammaglobulinemia (serum IgG &lt; 400 mg/dL)</li> <li>• Immunosuppression is attributed to <b>ONE</b> of the following: <ul style="list-style-type: none"> <li>○ Major surgery (for example, cardiac transplant)</li> <li>○ Hematologic malignancy</li> <li>○ Extensive burns</li> <li>○ Collagen-vascular disease</li> </ul> </li> <li>• Recurrent sinopulmonary infection or history of serious bacterial infection(s)</li> </ul>
<b>B-cell Chronic Lymphocytic Leukemia (CLL)</b>	<p>Treatment when <b>BOTH</b> of the following are met:</p> <ul style="list-style-type: none"> <li>• Serum IgG less than 500 mg/dL</li> <li>• Recurrent sinopulmonary infection or history of serious bacterial infection(s)</li> </ul>
<b>CMV Viremia</b>	<p>Treatment of refractory CMV viremia (e.g. persistent viral titers despite reduced immunosuppression, antiviral treatment) in cancer or solid organ transplant recipients.</p>
<b>HIV-infected Children</b>	<p><b>ONE of the following criteria is met:</b></p> <ul style="list-style-type: none"> <li>• Primary prophylaxis of bacterial infections when hypogammaglobulinemia (serum IgG &lt; 400 mg/dL) is present</li> <li>• Secondary prophylaxis of frequent recurrent serious bacterial infections (e.g., &gt; 2 serious bacterial infections in a 1-year period despite combination ART) when antibiotic prophylaxis is not effective</li> </ul>

<b>Multiple Myeloma</b>	<p>Approve for the duration noted if the patient meets <b>ONE</b> of the following (A or B)</p> <p>A. <u>Initial Therapy</u>. Approve for 6 months if the patient meets <b>BOTH</b> of the following (i and ii):</p> <ol style="list-style-type: none"> <li>i. Patient meets <b>ONE</b> of the following (a or b): <ol style="list-style-type: none"> <li>a) Patient has or is at risk of severe, recurrent infections according to the prescriber</li> <li>b) Patient will be starting, has taken, or is currently receiving chimeric antigen receptor (CAR)-T cell therapy OR bispecific antibody therapy;  <u>Note:</u> Examples of CAR-T cell therapy includes: Abecma (idecabtagene vicleucel intravenous infusion), Carvykti (ciltacabtagene autoleucel intravenous infusion).  <u>Note:</u> Examples of bispecific antibody therapy includes: Elrexfio (elranatamab-bcmm subcutaneous injection), Tecvayli (teclistamab-cqyv subcutaneous injection), Talvey (talquetamab-tgvs subcutaneous injection).</li> </ol> </li> <li>ii. The medication is prescribed by or in consultation with a hematologist, oncologist, or infectious disease specialist</li> </ol> <p>B. <u>Patient is Currently Receiving Immune Globulin</u>. Approve for 1 year.</p>
-------------------------	--

### III. Infectious Disease

Condition	Criteria for Use
<b>Measles - Post-Exposure Prophylaxis</b>	Prophylaxis when <b>ANY</b> of the following are met: <ul style="list-style-type: none"> <li>• Pregnant women without evidence of measles immunity</li> <li>• Severe primary immunodeficiency</li> <li>• Individuals who have received a bone marrow transplant until at least 12 months after finishing all immunosuppressive treatment, or longer in individuals who have developed graft-versus-host disease</li> <li>• Individual on treatment for acute lymphoblastic leukemia (ALL) within and until at least 6 months after completion of immunosuppressive chemotherapy</li> <li>• Individuals with a diagnosis of AIDS or HIV-infected persons with severe immunosuppression defined as CD4 percent &lt;15% (all ages) or CD4 count &lt;200 lymphocytes/mm<sup>3</sup> (aged &gt;5 years) and those who have not received MMR vaccine since receiving effective antiretroviral therapy (ART)</li> </ul>
<b>Toxic Shock Syndrome (Staphylococcal or Streptococcal)</b>	Acute treatment for <b>ANY</b> of the following: <ul style="list-style-type: none"> <li>• The infection is refractory to aggressive treatment</li> <li>• Presence of an undrainable focus</li> <li>• Persistent oliguria with pulmonary edema</li> </ul>
<b>Tetanus</b>	Post-exposure prophylaxis or treatment when Tetanus Immune Globulin is unavailable.
<b>Varicella</b>	Post-exposure prophylaxis when Varicella Immune Globulin is unavailable.

### IV. Transplantation

Condition	Criteria for Use
<b>BK Viremia</b>	Treatment of refractory BK viremia (e.g. persistent viral titers despite reduced immunosuppression) in kidney transplant recipients.
<b>Hematopoietic Cell Transplant (HCT)</b>	Prevention of infection in HCT recipients (for example, stem cell or bone marrow transplantation) with hypogammaglobulinemia (serum IgG < 400 mg/dL) and <b>EITHER</b> of the following: <ul style="list-style-type: none"> <li>• Within the first 100 days after transplant</li> </ul>

	<ul style="list-style-type: none"> <li>After 100 days and evidence of recurrent infections OR evidence of graft-versus-host-disease (GVHD)</li> </ul>
<b>Solid Organ Transplants</b>	<p>Treatment for <b>EITHER</b> of the following:</p> <ul style="list-style-type: none"> <li>Desensitization therapy prior to and immediately after transplantation <ul style="list-style-type: none"> <li>Authorization for a maximum dose of 2 grams/kg monthly for 4 consecutive months. Additional infusions at 12 months and 24 months may be authorized if the individual has not undergone transplantation.</li> </ul> </li> <li>Antibody-mediated rejection (AMR) <ul style="list-style-type: none"> <li>Initial authorization for a maximum dose of 2 grams/kg monthly for 3 months. Reauthorization for up to 3 months is dependent on documented beneficial clinical response.</li> </ul> </li> </ul>

## V. Hematology

<b>Condition</b>	<b>Criteria for Use</b>
<b>Anemia related to Chronic Parvovirus B19 Infection</b>	Treatment when there is a severe refractory anemia and evidence of viremia.
<b>Evan's Syndrome</b>	Treatment when there is failure, contraindication, or intolerance to available alternative therapies (azathioprine, cyclophosphamide, cyclosporine or prednisone).
<b>Fetal Alloimmune Thrombocytopenia (FAIT)</b>	<p>Treatment when <b>ALL</b> of the following:</p> <ul style="list-style-type: none"> <li>Documentation of maternal antibodies to paternal platelet antigen</li> <li><b>ONE</b> of the following: <ul style="list-style-type: none"> <li>Previous pregnancy complicated by FAIT</li> <li>Fetal blood sampling documents thrombocytopenia</li> </ul> </li> </ul>
<b>Hepatitis C-associated Thrombocytopenia</b>	<p>Treatment for <b>ANY</b> of the following:</p> <ul style="list-style-type: none"> <li>Clinically significant bleeding associated with thrombocytopenia</li> <li>Preoperative treatment prior to a major surgical procedure (for example, splenectomy)</li> <li>Receiving antiviral treatment for hepatitis C infection or treatment is contraindicated</li> </ul>
<b>HIV-associated Thrombocytopenia</b>	<p>Treatment for <b>ANY</b> of the following:</p> <ul style="list-style-type: none"> <li>Clinically significant bleeding associated with thrombocytopenia</li> <li>Preoperative treatment prior to a major surgical procedure (for example, splenectomy)</li> <li>Receiving treatment for HIV infection with antiretroviral therapy <b>AND</b> failure, contraindication, or intolerance to corticosteroids</li> </ul>
<b>Immune (Idiopathic) Thrombocytopenia (ITP) – Adult</b>	<p>Platelet count &lt; 30,000/mm<sup>3</sup> and <b>ONE</b> of the following are met:</p> <ul style="list-style-type: none"> <li>Clinical need to rapidly increase the platelet count (examples include, but are not limited to: active bleeding, prior to major surgical procedure, risk of cerebral hemorrhage)</li> <li>Not a candidate for splenectomy or experienced relapse post-splenectomy <b>AND</b> failure, contraindication, or intolerance to <b>ONE</b> of the following: <ul style="list-style-type: none"> <li>Corticosteroids</li> <li>Thrombopoietin receptor agonists (eltrombopag [Promacta®] or romiplostim [Nplate®])</li> <li>Rituximab (Rituxan®)</li> </ul> </li> </ul>
<b>Immune (Idiopathic) Thrombocytopenia (ITP) – Pediatric</b>	<p><b>ONE of the following are met:</b></p> <ul style="list-style-type: none"> <li>Clinical need to rapidly increase the platelet count (examples include, but are not limited to: active bleeding, prior to major surgical procedure, risk of cerebral hemorrhage)</li> </ul>

	<ul style="list-style-type: none"> <li>Prevention of bleeding during the first 12 months of persistent disease if responsive to previous treatment with IVIG</li> </ul>
<b>Immune Thrombocytopenia (ITP) - Pregnancy</b>	<p>Treatment when <b>ALL</b> of the following are met:</p> <ul style="list-style-type: none"> <li>Diagnosis of thrombocytopenia</li> <li>Failure, contraindication, or intolerance to corticosteroids or clinical need to rapidly increase the platelet count</li> </ul>
<b>Immunotherapy-Related Toxicities Associated with Checkpoint Inhibitor Therapy</b>	<p>Approve for the duration noted if the patient meets <b>ONE</b> of the following:</p> <p><u>Note:</u> Examples of checkpoint inhibitors are: Keytruda (pembrolizumab), Opdivo (nivolumab), Yervoy (ipilimumab), Tecentriq (atezolizumab), Bavencio (avelumab), Imfinzi (durvalumab).</p> <ul style="list-style-type: none"> <li><u>Initial Therapy.</u> Approve for 1 month if the individual meets <b>ONE</b> of the following criteria: <ul style="list-style-type: none"> <li>The individual has tried a systemic corticosteroid (for example, prednisone, methylprednisolone) and has not adequately responded to therapy</li> <li>The medication is being started with a systemic corticosteroid</li> <li>A corticosteroid is contraindicated per the prescriber</li> </ul> </li> <li><u>Individual is Currently Receiving Immune Globulin.</u> Approve for 6 months if the individual is having a positive response to therapy, as determined by the prescriber, and the prescriber has determined extended therapy is required.</li> </ul>
<b>Neonatal Isoimmune Hemolytic Disease in Conjunction with Phototherapy</b>	Acute treatment only.
<b>Post-transfusion purpura</b>	Acute treatment only.
<b>Warm Type Autoimmune Hemolytic Anemia</b> (characterized by predominance of IgG antibodies as opposed to cold type that is predominated by IgM antibodies)	Treatment when there is failure, contraindication, or intolerance to available alternative therapies (azathioprine, cyclophosphamide, cyclosporine, prednisone, plasmapheresis, or splenectomy).

## VI. Neurology

Condition	Criteria for Use
<b>Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), including Multifocal Acquired Demyelinating Sensory and Motor Neuropathy (MADSAM) (Lewis-Sumner Syndrome)</b>	<p><b>For initial authorization:</b> Approve for 3 months of treatment when <b>ALL</b> of the following <b>required</b> elements are met:</p> <ul style="list-style-type: none"> <li>Progressive or relapsing motor and/or sensory symptoms of more than one limb <b>AND</b> hyporeflexia or areflexia in affected limbs present for at least 2 months as documented by objective measurement</li> <li>Electrophysiologic findings indicate demyelinating neuropathy (3 of the following 4 criteria are met per the <u>American Academy of Neurology</u>): <ul style="list-style-type: none"> <li>Partial conduction block* of <math>\geq 1</math> motor nerve</li> <li>Reduced conduction velocity* of <math>\geq 2</math> motor nerves</li> <li>Prolonged distal latency* of <math>\geq 2</math> motor nerves</li> </ul> </li> </ul>

- Prolonged F-wave latencies\* of  $\geq 2$  motor nerves or the absence of F waves
- Other causes of demyelinating neuropathy have been excluded (from the European Federation of Neurological Societies and the Peripheral Nerve Society):
  - *Borrelia burgdorferi* infection (Lyme disease), diphtheria, drug or toxin exposure probably to have caused the neuropathy
  - Hereditary demyelinating neuropathy
  - Prominent sphincter disturbance
  - Diagnosis of multifocal motor neuropathy
  - IgM monoclonal gammopathy with high titer antibodies to myelin-associated glycoprotein
  - Other causes for a demyelinating neuropathy including POEMS syndrome, osteosclerotic myeloma, diabetic and non-diabetic lumbosacral radiculoplexus neuropathy, PNS lymphoma and amyloidosis.

\* Definitions from the American Academy of Neurology

- **Partial conduction block** is a drop of at least 20% in negative peak area or peak-to-peak amplitude and a change of < 15% in duration between proximal and distal site stimulation.
- **Possible conduction block or temporal dispersion** is a drop of at least 20% in negative peak area or peak-to-peak amplitude and a change of at least 15% in duration between proximal and distal site stimulation.
- **Reduced conduction velocity** is a velocity of < 80% of the lower limit of the normal range if the amplitude of the compound muscle action potential (CMAP) is > 80% of the lower limit of the normal range or < 70% of the lower limit if the CMAP amplitude is less than 80% of the lower limit.
- **Prolonged distal latency** is more than 125% of the upper limit of the normal range if the CMAP amplitude is more than 80% of the lower limit of the normal range or more than 150% of the upper limit if the CMAP amplitude is less than 80% of the lower limit.
- **Absent F wave or F-wave latency** is more than 125% of the upper limit if the CMAP amplitude is more than 80% of the lower limit or latency is more than 150% of the upper limit if the CMAP amplitude is less than 80% of the lower limit.

**When available**, results of other pertinent testing to support diagnosis should be provided. This includes, but is not limited to, the following:

- Cerebrospinal fluid (CSF) examination demonstrating elevated CSF protein with leukocyte count <10/mm<sup>3</sup>
- MRI showing gadolinium enhancement and/or hypertrophy of the cauda equina, lumbosacral or cervical nerve roots, or the brachial or lumbosacral plexuses
- Nerve biopsy showing unequivocal evidence of demyelination and/or remyelination by electron microscopy or teased fiber analysis

**For reauthorizations**, significant improvement in clinical condition has been documented by an objective measurement such as the inflammatory neuropathy cause and treatment group (INCAT) sensory sum score; assessment of grip strength via a hand-held dynamometer (e.g., Jamar, Vigorimeter); or Medical Research Council (MRC) scales or other similar, validated neurological scales **AND**, when applicable, a reduction in the level of sensory loss should be noted (see [Appendix 4](#)).

	<b>For long-term treatment</b> , evidence that the dose has been periodically reduced or the treatment withdrawn, and the effects measured.
<b>Guillain-Barré Syndrome (GBS)</b> – including Acute Inflammatory Demyelinating Polyneuropathy (AIDP)	Acute treatment when <b>ALL</b> of the following criteria have been met: <ul style="list-style-type: none"> <li>• Initial treatment within 4 weeks of the onset of symptoms</li> <li>• No concomitant use of plasmapheresis</li> <li>• Treatment may be repeated once but should not extend beyond 8 weeks from the onset of symptoms</li> </ul>
<b>Lambert-Eaton Myasthenic Syndrome (LEMS)</b>	Treatment when there is failure, contraindication, or intolerance to other symptomatic therapies (for example, acetylcholinesterase inhibitors such as Mestinon and immunosuppressants such as prednisone, azathioprine).
<b>Multifocal Motor Neuropathy (MMN)</b>	Treatment when <b>BOTH</b> of the following are present: <ul style="list-style-type: none"> <li>• Progressive symptoms present for at least 1 month</li> <li>• Diagnosis of <i>definite</i> or <i>probable</i> MMN as defined by the American Association of Neuromuscular and Electrodiagnostic Medicine (see <a href="#">Appendix 5</a>).</li> </ul>
<b>Myasthenia Gravis (MG)</b>	Treatment when <b>ANY</b> of the following is present: <ul style="list-style-type: none"> <li>• Before planned thymectomy or during the post-operative period following thymectomy</li> <li>• During an acute crisis (for example, significant dysphagia, respiratory failure, inability to perform physical activity) – duration of treatment should not exceed 5 days</li> <li>• During initiation of immunosuppressive treatment</li> <li>• For initial treatment of <b>refractory</b> myasthenia gravis and <b>ALL</b> of the following: <ul style="list-style-type: none"> <li>○ Documented failure or inadequate response to pyridostigmine</li> <li>○ Documented failure, intolerance or not a candidate (for example, ) for corticosteroid maintenance treatment</li> <li>○ Documented failure or inadequate response to nonsteroidal immunosuppressive treatment with at least one of the following: azathioprine, cyclosporine, cyclophosphamide, mycophenolate mofetil, methotrexate, tacrolimus</li> <li>○ Documented failure or contraindication to thymectomy for individuals who are anti-acetylcholine receptor (AChR) antibody positive</li> </ul> </li> </ul> <p>* Initial therapy for maintenance treatment for refractory MG may be approved up to 12 months.</p>
<b>Opsoclonus-Myoclonus-Ataxia Syndrome</b>	Treatment when there is a documented diagnosis.
<b>Rasmussen Encephalitis</b>	Treatment when there is failure to conventional therapy (corticosteroids, antiepileptic agents).
<b>Relapsing-Remitting Multiple Sclerosis (RRMS)</b>	Treatment as a single agent when there is failure to any <b>TWO</b> of the following products indicated for the treatment of relapsing-remitting multiple sclerosis: <ul style="list-style-type: none"> <li>• Dimethyl fumarate (Tecfidera®)*</li> <li>• Fingolimod (Gilenya™)*</li> <li>• Glatiramer acetate (Copaxone®)*</li> <li>• Interferon beta-1a (Avonex® or Rebif®)*</li> <li>• Interferon beta-1b (Betaseron®, Extavia®)*</li> <li>• Natalizumab (Tysabri®)*</li> <li>• Teriflunomide (Aubagio®)*</li> </ul> <p>* Individual plans may require prior authorization or pre-certification.</p>
<b>Stiff Person Syndrome (Moersch-Woltmann Syndrome)</b>	Treatment when <b>BOTH</b> of the following are met: <ul style="list-style-type: none"> <li>• Anti-GAD antibody testing performed</li> </ul>

	<ul style="list-style-type: none"> <li>Failure to available standard medical therapy (for example, diazepam, baclofen, phenytoin, clonidine, or tizanidine)</li> </ul>
--	--

## VII. Rheumatology

Condition	Criteria for Use
<b>Dermatomyositis or Polymyositis</b>	Treatment when <b>BOTH</b> of the following are present: <ul style="list-style-type: none"> <li>Documented dermatomyositis or polymyositis established by biopsy</li> <li><b>ONE</b> of the following               <ul style="list-style-type: none"> <li>Failure of standard medical therapy (corticosteroids AND immunosuppressives)</li> <li>Profound, rapidly progressive and/or potentially life threatening muscular weakness</li> </ul> </li> </ul>
<b>Kawasaki disease</b>	Acute treatment when given in conjunction with aspirin within ten days of onset of symptoms.

## VIII. Dermatology

Condition	Criteria for Use
<b>Autoimmune mucocutaneous blistering diseases; such as:</b> <ul style="list-style-type: none"> <li><b>Bullous Pemphigoid</b></li> <li><b>Epidermolysis Bullosa Acquisita</b></li> <li><b>Pemphigoid (a.k.a., Cicatricial Pemphigoid)</b></li> <li><b>Pemphigus Foliaceus</b></li> <li><b>Pemphigus Vulgaris</b></li> </ul>	Treatment when <b>EITHER</b> of the following criteria is met: <ul style="list-style-type: none"> <li>Failure, contraindication or intolerance of conventional therapy (corticosteroids, azathioprine, cyclophosphamide, mycophenolate mofetil)</li> <li>Rapidly progressive disease in which a clinical response cannot be affected quickly enough using conventional agents. In these situations, IVIG therapy should be given along with conventional treatment(s) and the IVIG used only until conventional therapy takes effect</li> </ul> <p><b>Note:</b> IVIG for the treatment of autoimmune mucocutaneous blistering disease is covered only for short-term therapy (<b>no longer than 6 consecutive months</b>) and not as a maintenance therapy</p>
<b>Stevens–Johnson Syndrome (SJS)/Toxic Epidermal Necrolysis (TEN)</b>	Acute treatment only.

### See appendices for the following information:

- [Appendix 1](#) – Standard Reference Ranges for Serum Immunoglobulin Levels
- [Appendix 2](#) – Standard Reference Ranges for Serum Immunoglobulin G Subclasses (G1, G2, G3, G4)
- [Appendix 3](#) – Selected Genetic Based Primary Immunodeficiency (PID) Disorders
- [Appendix 4](#) – Examples of Objective Measurements to Assess Clinical Response (CIDP Reauthorization Criteria)
- [Appendix 5](#) – American Association of Neuromuscular and Electrodiagnostic Medicine Consensus Criteria for the Diagnosis of Multifocal Motor Neuropathy

When coverage is available and medically necessary, the dosage, frequency, duration of therapy, and site of care should be reasonable, clinically appropriate, and supported by evidence-based literature and adjusted based upon severity, alternative available treatments, and previous response to therapy.

Receipt of sample product does not satisfy any criteria requirements for coverage.

## Reauthorization Criteria

Continuation of immune globulin therapy is considered medically necessary for all covered diagnoses when **ALL** of the following are met:

1. The above medical necessity criteria have been met prior to the start of immune globulin therapy
2. The medical condition or disease under treatment has not fully resolved and the treatment has not exceeded any applicable duration listed below.
3. There continues to be a sustained beneficial response to IVIG as evidenced by treatment notes or a clinical narrative detailing progress to date and the expected frequency and duration of any proposed IVIG use going forward.
4. The requested frequency and dosage of IVIG is supported by evidence-based literature.
5. Where clinically appropriate, titration has occurred to the minimum dose and frequency to achieve sustained clinical effect.

## Authorization Duration

**Initial authorization** is up to 6 months unless otherwise stated within the [Specific Medical Necessity Criteria by Condition](#).

**Reauthorization** is up to 6 months (up to 12 months for CIDP, PID and for *refractory* MG).

## Conditions Not Covered

Any other use is considered not medically necessary, including the following (this list may not be all inclusive; criteria will be updated as new published data are available):

1. Hashimoto encephalopathy
2. Inclusion body myositis (IBM)
3. Lyme neuropathy
4. Neonatal sepsis
5. Pediatric acute-onset neuropsychiatric syndrome (PANS) and Pediatric autoimmune neuropsychiatric disorder associated with group A streptococci (PANDAS)
6. Primary progressive multiple sclerosis (MS) and secondary progressive MS, acute MS exacerbations, or clinically isolated syndrome
7. Recurrent pregnancy loss

## Coding Information

- Note:** 1) This list of codes may not be all-inclusive.  
2) Deleted codes and codes which are not effective at the time the service is rendered may not be eligible for reimbursement.

**Considered Medically Necessary when criteria in the applicable policy statements listed above are met:**

CPT®* Codes	Description
90283	Immune globulin (IgIV), human, for intravenous use
90284	Immune globulin (SCIg), human, for use in subcutaneous infusions, 100 mg, each

HCPCS Codes	Description
J1459	Injection, immune globulin (Privigen), intravenous, nonlyophilized (e.g., liquid), 500 mg
J1551	Injection, immune globulin (Cutaquig), 100 mg
J1552	Injection, immune globulin (Alyglo), 500 mg
J1553	Injection, immune globulin (yimmugo), 100 mg (effective date 4/1/2026)

HCPCS Codes	Description
J1554	Injection, immune globulin (Asceniv), 500 mg
J1555	Injection, immune globulin (Cuvitru), 100 mg
J1556	Injection, immune globulin (Bivigam), 500 mg
J1557	Injection, immune globulin, (Gammaplex), intravenous, nonlyophilized (e.g., liquid), 500 mg
J1558	Injection, immune globulin (Xembify), 100 mg
J1559	Injection, immune globulin (Hizentra), 100 mg
J1561	Injection, immune globulin, (Gamunex/Gamunex-C/Gammaked), nonlyophilized (e.g., liquid), 500 mg
J1566	Injection, immune globulin, intravenous, lyophilized (e.g., powder), not otherwise specified, 500 mg
J1568	Injection, immune globulin, (Octagam), intravenous, nonlyophilized (e.g., liquid), 500 mg
J1569	Injection, immune globulin, (Gammagard liquid), nonlyophilized, (e.g., liquid), 500 mg
J1572	Injection, immune globulin, (Flebogamma/Flebogamma Dif), intravenous, nonlyophilized (e.g., liquid), 500 mg
J1575	Injection, immune globulin/hyaluronidase, 100 mg immunoglobulin
J1576	Injection, immune globulin (Panzyga), intravenous, non-lyophilized (e.g., liquid), 500 mg

\*Current Procedural Terminology (CPT®) ©2025 American Medical Association: Chicago, IL.

## Background

### OVERVIEW

Immune globulin intravenous (IVIG) products are concentrated human immunoglobulins, primarily immunoglobulin G (IgG).

All of these products (except Octagam 10%) are FDA-approved for replacement therapy in patients with **primary immune deficiencies** due to defects in humoral immunity. The following indications are FDA approved:

- **B-cell chronic lymphocytic leukemia (CLL)**, for prevention of bacterial infections in patients with hypogammaglobulinemia and/or recurrent infections.<sup>6,18,21</sup>
- **Chronic inflammatory demyelinating polyneuropathy (CIDP)**, to improve neuromuscular disability and impairment and for maintenance therapy to prevent relapse.<sup>5,7,9,12,15,67</sup>
- **Dermatomyositis (or polymyositis)**. Octagam 10% is indicated for the treatment of dermatomyositis in adults.<sup>11</sup> Patients with dermatomyositis treated with Octagam were under treatment with corticosteroids and/or maximally two immune-suppressants OR patients had previous failure or intolerance with a corticosteroid and at least one additional immunosuppressive drug.<sup>33</sup> IVIG may be considered amongst the treatment options for patients with polymyositis not responding to first line immunosuppressive treatment.<sup>32</sup>
- **Idiopathic (immune) thrombocytopenic purpura (ITP)**, acute and chronic, when a rapid rise in platelet count is needed to prevent and/or control bleeding or to allow a patient with ITP to undergo surgery.<sup>2,6-9,11,12,15,23-25</sup>
- **Kawasaki disease** in pediatric patients for the prevention of coronary artery aneurysm.<sup>6,26</sup> The American Heart Association and the American Academy of Pediatrics recommend initial therapy with 2 g of IVIG per kg as a single intravenous (IV) dose given over 10 to 12 hours.<sup>26</sup> The dose can be repeated if needed.
- **Multifocal motor neuropathy** in adults as maintenance therapy to improve muscle strength and disability.<sup>5</sup>
- **Primary humoral immune deficiency (PID)**, for replacement therapy, including but not limited to the humoral immune defect in the following conditions: common variable immunodeficiency, X-linked agammaglobulinemia [congenital agammaglobulinemia], Wiskott-Aldrich Syndrome, and severe combined immunodeficiencies.<sup>1-3,5-10,12,15,16,25,53,80</sup> Gammagard Liquid 10%, Gammaked, and Gamunex-C may be administered via IV or subcutaneous infusion for primary immunodeficiency.<sup>5,7,9</sup> IVIG is also indicated for measles prophylaxis in individuals with PID who have been exposed to measles or who are at high risk of measles exposure.<sup>3,7-10,12,13,17,25,45,80</sup>

IVIg is prepared from pooled plasma collected from a large number of human donors.<sup>1-3,5-12,15,16,25</sup> The donors in a typical pool of plasma have a wide range of antibodies against infectious agents. These products have IgG subclasses similar to that found in normal humans. Asceniv contains not only antibodies which satisfy the requirement to treat patients with PID, it also has elevated levels of respiratory syncytial virus (RSV) antibodies.<sup>19</sup>

IVIg also is used for many off-label indications. Much of the evidence for clinical effectiveness of IVIg is anecdotal (i.e., case reports, open series, or cohort studies). Some conditions have been studied in controlled trials. Usually, IVIg is indicated only if standard approaches have failed, become intolerable, or are contraindicated.

- **Antibody-mediated rejection (ABMR) in transplantation:** Current strategies for treatment of antibody-mediated rejection include plasmapheresis, IVIg, and T-cell or B-cell-depleting agents.<sup>75</sup> Although there are no controlled trials regarding the most appropriate treatments, the benefits of immune globulin have been well described and has been used as the standard-of-care (along with plasmapheresis) in multiple studies.<sup>18,76</sup> Clinical practice guidelines (2009 Kidney Disease: Improving Global Outcomes) recommends a combination of corticosteroids, plasmapheresis, IVIg, anti-CD20 antibody, and lymphocyte-depleting antibody for antibody-mediated rejection.<sup>76,77</sup> As in desensitization therapy, much of the information for IVIg use is in patients with kidney transplants, but the same principles apply to transplantation of other organs and tissues. Immune globulin has been used in lung transplant patients to treat ABMR<sup>20,44,78</sup> and a scientific statement from the American Heart Association states that primary therapy for ABMR in patients with heart transplants may include IVIg, plasmapheresis, high-dose corticosteroids, and anti-lymphocyte antibodies.<sup>36</sup>
- **Autoimmune mucocutaneous blistering diseases (pemphigus vulgaris, pemphigus foliaceus, bullous pemphigoid, mucous membrane pemphigoid [cicatricial pemphigoid], and epidermolysis bullosa acquisita):** Conventional therapy (a systemic corticosteroid and an immunosuppressive agent) is started at the same time or before IVIg. Many case reports and uncontrolled case series suggest benefit of IVIg in patients with recalcitrant disease or in those with contraindications to conventional therapy.<sup>28-30</sup> International expert recommendations for the management of pemphigus note that first-line treatment includes corticosteroids and anti-CD20 monoclonal antibodies. First-line corticosteroid-sparing agents include azathioprine and mycophenolate mofetil, and other corticosteroid-sparing agents including IVIg.<sup>2</sup>
- **Aquaporin-4 Immunoglobulin Antibodies (AQP4-IgG)-positive Neuromyelitis Optica Spectrum Disorder (NMOSD):** NMOSD is an inflammatory disorder of the central nervous system characterized by severe, immune-mediated demyelination and axonal damage.<sup>32</sup> The range of NMOSD has expanded to include patients with aquaporin-4 (AQP4) antibody positivity who have single or recurrent attacks of optic neuritis, myelitis, or brainstem syndromes. Antibodies against AQP4 are present in the majority of NMOSD patients.<sup>52</sup> The loss of AQP4 expression leads to loss of nervous system cells and neuron damage. Products recommended for long-term management of the condition include rituximab, azathioprine, mycophenolate, and therapeutic antibodies, such as Soliris® (eculizumab intravenous infusion), Ultomiris® (ravulizumab-cwvz intravenous infusion), Uplizna® (inebilizumab-cdon intravenous infusion), and Enspryng® (satralizumab-mwge subcutaneous injection). IVIg is recommended in children or in case of contraindications to other long-term therapies.<sup>52</sup>
- **Cytomegalovirus (CMV) pneumonitis or pneumonia in patients with cancer or transplant-related infection:** For CMV pneumonia, therapy generally consists of antivirals (e.g., ganciclovir, foscarnet). The National Comprehensive Cancer Network (NCCN) guidelines on prevention and treatment of cancer-related infections (version 3.2024 – September 23, 2024) lists IVIg as an adjunctive therapy for CMV pneumonitis, but notes that IVIg use as an antiviral is controversial.<sup>31</sup>
- **Desensitization therapy prior to and immediately after transplantation:** Most of the information on use of IVIg for desensitization is in patients with kidney transplantation but many of the same principles apply to transplantation of other organs and tissues.<sup>34,35</sup> Current protocols include using low-dose IVIg with plasma exchange or high-dose IVIg with or without B-cell depletions with rituximab.<sup>18</sup>
- **Guillain Barré syndrome (GBS):** The American Academy of Neurology recommends IVIg in patients who require aid to walk within 2 or 4 weeks from the onset of neuropathic symptoms.<sup>37</sup> The European Academy of Neurology/Peripheral Nerve Society guideline on diagnosis and treatment of GBS (2023) recommends IVIg or plasma exchange in patients for up to 4 weeks after onset of weakness.<sup>38</sup> For patients who are > 4 weeks of onset and are still deteriorating, other diagnoses should be considered. The guidelines additionally note that observational data indicates that a repeated course of IVIg can be effective in case of treatment-related fluctuation.

- **Hematologic neoplasm-associated hypogammaglobulinemia or hypogammaglobulinemia after B-cell targeted therapies (secondary immunodeficiency):** Clinical guidelines for immunoglobulin use by the National Health Service-England note secondary antibody deficiency can be hypogammaglobulinemia associated with therapeutic monoclonals targeted at B-cells and plasma cells, non-Hodgkin's lymphoma, CLL, multiple myeloma, or other relevant B-cell malignancies.<sup>27</sup> NCCN guidelines regarding management of immunotherapy-related toxicities (version 2.2024 – October 25, 2024) recommends that after anti-CD19 chimeric antigen receptor (CAR)-T cell therapy, IVIG replacement should be considered for patients with serum IgG levels < 400 to 600 mg/dL and serious or recurrent infections.<sup>73</sup>
- **Hematopoietic cell transplantation (HCT) to prevent infections:** HCT is defined as transplantation of any blood- or marrow-derived hematopoietic stem cells, regardless of transplant type (i.e., allogeneic or autologous) or cell source (i.e., bone marrow, peripheral blood, or umbilical cord blood). With regard to IVIG, guidelines recommend IVIG for prevention or preemptive treatment of specific infections in HCT recipients.<sup>39</sup> In adult or adolescent HCT recipients (allogeneic or autologous), IVIG is used to prevent infections in those with severe hypogammaglobulinemia (i.e., serum IgG < 400 mg/dL) during the first 100 days after HCT. In pediatric patients, IVIG is indicated in those with an allogeneic HCT if hypogammaglobulinemia is severe during the first 100 days after HCT. For prevention of infections beyond 100 days post-HCT (allogeneic or autologous), IVIG is recommended in recipients with severe hypogammaglobulinemia (i.e., serum IgG < 400 mg/dL). Guidelines from the American Society for Blood and Marrow Transplantation make recommendations for IVIG dosing in HCT recipients to prevent infectious complications.<sup>39</sup> During the first 100 days after HCT, the dose in adults and adolescents is 0.5 g/kg per week. The IVIG dose should be individualized to maintain trough (pre-dose) serum IgG > 400 to 500 mg/dL. The dose in allogeneic pediatric HCT patients is 0.4 g/kg per month, adjusted to keep IgG > 400 mg/dL. Higher and more frequent dosing may be necessary in patients for prevention of early disease after HCT because the half-life of IVIG is reduced to between 1 to 10 days in this population. Dosing for > 100 days post-HCT is 0.5 g/kg given every 3 to 4 weeks. The dose is not adjusted using serum IgG level in patients with multiple myeloma or malignant macroglobulinemia. NCCN guidelines on prevention and treatment of cancer-related infections discussed similar recommendations.<sup>31</sup>
- **Human immunodeficiency virus (HIV)- or Hepatitis C-associated thrombocytopenia:** Secondary ITP can occur in patients with HIV infection.<sup>23,24</sup> It can also occur in patients with Hepatitis C. The American Society of Hematology (ASH) guidelines for ITP recommend initial treatment with corticosteroids, IVIG, or Rh0(D) immune globulin for patients with secondary ITP due to HIV. ASH also recommends IVIG for secondary ITP associated with Hepatitis C.<sup>23,24</sup>
- **HIV-infected infants and children to prevent recurrent infections:** IVIG is recommended to prevent serious bacterial infections in HIV-infected children who have hypogammaglobulinemia (IgG < 400 mg/dL).<sup>40</sup> Clinicians providing care for adolescents are advised to use the US Department of Health and Human Services Adult and Adolescent HIV-guideline for the care of post-pubertal adolescents (sexual maturity rating [SMR] four and five) and to use the pediatric guideline for guidance on the care of adolescents at SMR 3 or lower.<sup>40</sup>
- **Immune-Mediated Necrotizing Myopathy:** Muscle weakness is the predominant clinical feature and sometimes severely affects the lower limbs.<sup>56</sup> Pharyngeal muscles may also be affected and dysphagia is common. Serum creatine kinase (CK) is also high. The CK value can widely vary but is often well above 1,000 IU/L.<sup>62</sup> Myositis-specific antibodies are often detected (e.g., anti-HMGCR antibodies, anti-SRP antibodies). Muscle imaging and biopsy can also be useful to confirm the diagnosis. International consensus guidelines recommend IVIG as a second-line agent for anti-HMGCR to avoid long-term disability.<sup>63</sup> For patients with anti-HMGCR monotherapy with IVIG has also been used.<sup>62</sup>
- **Immunotherapy-related toxicities associated with checkpoint inhibitor therapy:** NCCN guidelines for the management of immunotherapy-related toxicities (version 2.2024 – October 25, 2024) recommends IVIG for the management of suspected myocarditis/pericarditis/large vessel vasculitis, severe pneumonitis after 48 hours of methylprednisolone therapy, severe myasthenia gravis, encephalitis, moderate or severe GBS, demyelinating disease, myositis, bullous dermatitis, and Stevens-Johnson syndrome/toxic epidermal necrolysis.<sup>73</sup> The American Society of Clinical Oncology also has practice guidelines on the management of immune-related adverse events in patients treated with checkpoint inhibitor therapy.<sup>74</sup> These practice guidelines note that corticosteroids may be administered for toxicities and refractory or severe cases may require other immunosuppressive therapies or IVIG.

- **Lambert-Eaton Myasthenic Syndrome:** Limited, but moderate- to high-quality evidence from randomized controlled trials have shown that 3,4-diaminopyridine or IVIG was associated with improved muscle strength score and compounded muscle action potential amplitudes. IVIG may be used as an alternative in patients who do not respond or do not tolerate other therapies.<sup>18</sup>
- **Multiple myeloma:** Patients with multiple myeloma are often functionally hypogammaglobulinemic with total immunoglobulin production being elevated, but the repertoire of antibody production restricted.<sup>31</sup> The NCCN guidelines on multiple myeloma (version 1.2025 – September 17, 2024) recommends immune globulin replacement with CAR-T cell and bispecific antibody therapies, based on clinical context.<sup>42</sup> NCCN also notes replacement can be considered for IgG < 400 mg/dL and recurrent life-threatening infections, making sure to consider the portion of IgG that is clonal.
- **Multiple sclerosis, acute severe exacerbation or relapses:** Medication options for relapse management include high dose corticosteroids, intramuscular adrenocorticotrophic hormone, plasmapheresis, and IVIG. IVIG is sometimes used to treat relapses that do not respond to corticosteroids.<sup>43</sup> During pregnancy, relapses severe enough to require treatment can be safely managed with a short-term course of corticosteroids after the first trimester. Methylprednisolone is the preferred agent because it is metabolized before crossing the placenta.<sup>43</sup>
- **Myasthenia gravis:** Recommendations from an international consensus guidance statement for management of adult or juvenile myasthenia gravis include the use of IVIG in some patients.<sup>65</sup> Symptomatic and immunosuppressive treatment of myasthenia gravis includes pyridostigmine as initial therapy in most patients. Corticosteroids or immunosuppressive therapies are used in all patients with myasthenia gravis who have not met treatment goals after an adequate trial of pyridostigmine. A nonsteroidal immunosuppressive agent (e.g., azathioprine, cyclosporine, mycophenolate mofetil, methotrexate, tacrolimus) should be used alone when corticosteroids are contraindicated or refused. In patients with refractory myasthenia gravis, chronic IVIG and chronic plasma exchange (PLEX), cyclophosphamide, or rituximab may be used. PLEX and IVIG are recommended as short-term treatments in patients with myasthenia gravis with life-threatening effects such as respiratory insufficiency or dysphagia, to prepare for surgery in patients with significant bulbar dysfunction, when rapid response is needed, when other treatments are not adequate, and before starting corticosteroids if necessary to prevent or minimize exacerbations. IVIG can be considered as maintenance therapy in patients with refractory myasthenia gravis or in patients with relative contraindications to immunosuppressive agents. Refractory myasthenia gravis is defined as the post intervention status of unchanged or worse after corticosteroids and at least two other immunosuppressive agents used in adequate doses for an adequate duration, with persistent symptoms or side effects that limit functioning as defined by the patient or physician. The international consensus guidance statement for myasthenia gravis<sup>65</sup> recommends an initial dose of 2 g/kg given in divided doses over 2 to 5 days. For maintenance therapy, the recommended dose is 0.4 to 1 g/kg given every 4 weeks; an attempt to decrease frequency can be made over time. If additional treatment is required, the dose should be adjusted based on the response.
- **Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD):** International MOGAD Panel proposed criteria reports the central nervous system demyelinating features of this condition include optic neuritis (most common feature), acute disseminated encephalomyelitis (with or without optic neuritis), transverse myelitis, and other less common presentations.<sup>69</sup> Serological evidence of myelin oligodendrocyte glycoprotein (MOG)-IgG is also seen. MOGAD can present as an acute attack and relapses of attacks; a diagnosis of multiple sclerosis should be excluded. Disease flares in MOGAD are generally treated with high dose corticosteroids.<sup>70</sup> A typical dose used for IVIG is 0.4 g/kg/day for 5 days. Maintenance therapy is generally offered in patients who have had two or more attacks; however, exceptions are noted in cases to prevent further disability.<sup>70</sup> For maintenance infusions, a loading dose of 0.4 g/kg/day for 5 days can be given, followed by treatment every 4 weeks with a dose of 0.4 g/kg to 2 g/kg.
- **Passive immunization for measles (post-exposure prophylaxis):** When administered within 6 days of exposure, immune globulin (IG) can prevent or modify measles in patients who are nonimmune.<sup>13</sup> IG therapy is not indicated in persons who have received one dose of measles-containing vaccine at ≥ 12 months, unless the patient is severely immunocompromised. The Advisory Committee on Immunization Practices (ACIP) recommends the use of IG therapy for post-exposure prophylaxis of measles in the following patients who are at risk for severe disease and complication from measles: infants < 12 months of age, pregnant women without evidence of measles immunity, and severely immunocompromised persons.<sup>13</sup> For infants < 12 months of age, intramuscular IG is used; infants 6 through 11 months of age

can receive measles, mumps, and rubella vaccine instead of IG if given within 72 hours of exposure. IVIG is used for pregnant women and severely immunocompromised patients. ACIP recommends 400 mg/kg as an IV infusion.<sup>13</sup> The American College of Obstetricians and Gynecologists Practice Advisory on pregnant patients during a measles outbreak (2024) recommends pregnant patients with suspected measles exposure, but without immunity (or those who cannot readily show evidence of immunity), should receive IVIG 400 mg/kg within 6 days of exposure.<sup>4</sup>

- **Post-exposure prophylaxis for varicella OR treatment or post-exposure prophylaxis for tetanus:** Children infected with HIV who lack evidence of immunity to varicella or who have severe immune suppression should receive VariZIG® (human varicella-zoster immune globulin for intramuscular administration)<sup>40,41</sup> An alternative to varicella-zoster immune globulin for passive immunization is oral valacyclovir or acyclovir beginning 7 days after exposure, and if this is not available, IVIG administered once within 10 days after exposure.<sup>41</sup> VariZIG is indicated for post-exposure prophylaxis in high risk individuals.<sup>47</sup> The dose is 400 mg/kg given once.<sup>40,41,46</sup> Per the Centers for Disease Control and Prevention, if tetanus immune globulin is not available, clinicians can use immune globulin at a dose of 200 to 400 mg/kg.<sup>48</sup>
- **Parvovirus B19 infection and pure red blood cell aplasia, immunologic subtype:** In immunosuppressed patients lacking neutralizing antibodies, IVIG has been useful for the treatment of persistent B19 infection.<sup>49</sup> The guidelines from the American Society of Transplantation Infectious Diseases Community of Practice state that IVIG is frequently used for the treatment of solid organ transplant recipients with symptomatic parvovirus B19 infection.<sup>66</sup> A Canadian expert panel of hematologists recommend prednisone followed by cyclophosphamide or cyclosporine as first-line therapy for immunologic type pure red blood cell aplasia.<sup>22</sup> The panel considers IVIG a reasonable second-line option for this serious condition. Recent reviews note that 200 to 400 mg/kg/day for 5 to 10 days is considered the recommended treatment course.<sup>79</sup>
- **Stiff-Person Syndrome (Moersch-Woltman Syndrome):** Per the European Federation of Neurological Societies, IVIG should be reserved for patients who have no symptomatic relief after the use of diazepam and/or baclofen and have severe disability in carrying out daily activities.<sup>32</sup>
- **Thrombocytopenia, feto-neonatal alloimmune:** Antenatal therapy with IVIG administered to the mother is effective in increasing fetal platelet counts in neonatal alloimmune thrombocytopenia.<sup>50,51</sup> First-line therapy for newborns with fetal/neonatal alloimmune thrombocytopenia is antigen-negative compatible platelets; IVIG is adjunctive therapy.

## Appendix 1

### Standard Reference Ranges for Serum Immunoglobulin Levels

The following standard reference ranges may be used for evaluation if the testing laboratory's reference ranges are not submitted.

Normal Serum Immunoglobulin Levels (mg/dL)			
Age	IgA	IgG	IgM
0 – 30 days	1 – 7	<b>611 – 1542</b>	0 – 24
1 mo	1 – 53	<b>241 – 870</b>	19 – 83
2 mo	3 – 47	<b>198 – 577</b>	16 – 100
3 mo	5 – 46	<b>169 – 558</b>	23 – 85
4 mo	4 – 72	<b>188 – 536</b>	26 – 96
5 mo	8 – 83	<b>165 – 781</b>	31 – 103
6 mo	8 – 67	<b>206 – 676</b>	33 – 97
7 – 8 mo	11 – 89	<b>208 – 868</b>	32 – 120
9 – 11 mo	16 – 83	<b>282 – 1026</b>	39 – 142
1 yr	14 – 105	<b>331 – 1164</b>	41 – 164
2 yr	14 – 122	<b>407 – 1009</b>	46 – 160
3 yr	22 – 157	<b>423 – 1090</b>	45 – 190
4 yr	25 – 152	<b>444 – 1187</b>	41 – 186
5 – 7 yr	33 – 200	<b>608 – 1229</b>	46 – 197
8 – 9 yr	45 – 234	<b>584 – 1509</b>	49 – 230

Immunoglobulins, Serum Quantitative. Effective February 16, 2016. Accessed 3/14/2017.

Available at: <http://www.aruplab.com/guides/ug/tests/0050630.jsp>

## Appendix 2

### **Standard Reference Ranges for Serum Immunoglobulin G Subclasses (1, 2, 3, and 4)**

The following standard reference ranges may be used for evaluation if the testing laboratory's reference ranges are not submitted.

<b>Normal Serum Immunoglobulin G Subclass Levels (mg/dL)</b>				
<b>Age</b>	<b>IgG1</b>	<b>IgG2</b>	<b>IgG3</b>	<b>IgG4</b>
Cord Blood	435-1084	143-453	27-146	1-47
0-2 months	218-498	40-167	4-23	1-33
3-5 months	143-394	23-147	4-70	1-14
6-8 months	190-388	37-60	12-62	1-16
9-23 months	288-880	30-327	13-82	1-65
2 years	170-950	22-440	4-69	0-120
3-4 years	290-1065	28-315	4-71	0-90
5-6 years	330-1065	57-345	8-126	2-116
7-8 years	225-1100	42-375	9-107	0-138
9-10 years	390-1235	61-430	10-98	1-95
11-12 years	380-1420	73-455	16-194	1-153
13-14 years	165-1440	71-460	12-178	2-143
15 years & older	240-1118	124-549	21-134	7-89

Immunoglobulin G Subclass Levels (1, 2, 3, 4). Effective February 16, 2016. Accessed 3/14/2017  
Available at: <http://www.aruplab.com/guides/ug/tests/0050577.jsp>

## Appendix 3

### **Selected Genetic Based Primary Immunodeficiency Syndrome (PID)**

<b>Condition</b>	<b>Features</b>
Autosomal recessive agammaglobulinemia (ARA)	<ul style="list-style-type: none"> <li>• Recurrent sinopulmonary bacterial infections</li> <li>• Extremely low or absent IgG, IgM and IgA</li> <li>• IGHM, CD79a, CD199b, BLNK, or LRRC8 gene impaired</li> </ul>
Autosomal recessive hyperimmuno-globulin M syndrome (HIM)	<ul style="list-style-type: none"> <li>• Group of disease characterized by normal or elevated levels of serum IgM with low or absent IgG and IgA levels.</li> <li>• AICDA or UNG gene impaired</li> </ul>
Combined immunodeficiency disorders (not all-inclusive)	<ul style="list-style-type: none"> <li>• Ataxia-telangiectasia (A-T)</li> <li>• Wiskott Aldrich syndrome (WAS),</li> <li>• DiGeorge syndrome (DGS)</li> <li>• Nijmegen breakage syndrome (NBS)</li> <li>• Warts, hypogammaglobulinemia, immunodeficiency, and myelokathexis (WHIM)</li> </ul>
Congenital Hypogammaglobulinemia	<ul style="list-style-type: none"> <li>• Late onset</li> <li>• Inducible Co-Stimulator (ICOS) impaired</li> </ul>
Congenital/X-linked agammaglobulinemia (XLA)	<ul style="list-style-type: none"> <li>• Bruton's Disease</li> <li>• BTK gene impaired</li> </ul>
Hyperimmuno-globulinemia E syndrome (HIES)	<ul style="list-style-type: none"> <li>• Includes recurrent lung and skin infections (e.g., chronic eczema)</li> <li>• Facies with coarse and/or asymmetric features</li> <li>• Type 1 is characterized by STAT3 mutation (also known as Job syndrome)</li> <li>• Type 2 is characterized by DOCK8 mutation</li> </ul>
Hypogammaglobulinemia, unspecified	<ul style="list-style-type: none"> <li>• Primary hypogammaglobulinemia</li> <li>• Normal cellular immunity</li> </ul>

	<ul style="list-style-type: none"> <li>Does not meet diagnostic criteria for a specific disorder</li> </ul>
ICF Syndrome	<ul style="list-style-type: none"> <li>Abnormal Facies</li> <li>Respiratory Tract Infections</li> <li>Hypogammaglobulinemia</li> <li>Characteristic Chromosomal Abnormalities</li> </ul>
Specific Antibody Deficiency (SAD)	<ul style="list-style-type: none"> <li>Generally does not require IVIG replacement for control of recurrent bacterial infections</li> <li>Rare individuals will have infection susceptibility with normal vaccine responses</li> </ul>
Selective IgG subclass deficiencies (IGGSD)	<ul style="list-style-type: none"> <li>Persistent absence of IgG1, IgG2, and/or IgG3</li> <li>Generally does not require IVIG replacement for control of recurrent bacterial infections</li> <li>Rare individuals will have infection susceptibility with normal vaccine responses</li> </ul>
Severe combined immunodeficiency disorder (SCID)	<ul style="list-style-type: none"> <li>Complete absence of specific immunity</li> <li>Most susceptible to entire range of possible pathogens</li> <li>May be life threatening</li> </ul>
Transient hypogammaglobulinemia of infancy	<ul style="list-style-type: none"> <li>Recurrent bacterial sinopulmonary infections and frequent viral illnesses</li> <li>Only requires short-term IVIG replacement for recurrent severe bacterial infections</li> </ul>

**Appendix 4**  
**Examples of Objective Measurements to Assess Clinical Response**  
**(CIDP Reauthorization Criteria)**

Measurement Tool	Description
Medical Research Council (MRC) Scale for Muscle Strength - MRC Sum Score	<ul style="list-style-type: none"> <li>Ranges from 0 (“total paralysis”) to 60 (“normal strength”)</li> <li>Summation of the MRC grades (range, 0–5) given in full numbers of the following muscle pairs - upper arm abductors, elbow flexors, wrist extensors, hip flexors, knee extensors, foot dorsal flexors</li> <li>Individual effort is graded on a scale of 0-5 as follows: <ul style="list-style-type: none"> <li>Grade 5 - Muscle contracts normally against full resistance.</li> <li>Grade 4 - Muscle strength is reduced but muscle contraction can still move joint against resistance.</li> <li>Grade 3 - Muscle strength is further reduced such that the joint can be moved only against gravity with the examiner's resistance completely removed. As an example, the elbow can be moved from full extension to full flexion starting with the arm hanging down at the side.</li> <li>Grade 2 - Muscle can move only if the resistance of gravity is removed. As an example, the elbow can be fully flexed only if the arm is maintained in a horizontal plane.</li> </ul> </li> </ul>

	<ul style="list-style-type: none"> <li>○ Grade 1 - Only a trace or flicker of movement is seen or felt in the muscle or fasciculations are observed in the muscle.</li> <li>○ Grade 0 - No movement is observed</li> </ul>
Hand-held dynamometer (e.g., Jamar, Vigorimeter)	Hand held device for measuring grip strength
Inflammatory Neuropathy Cause and Treatment group (INCAT) sensory sum score	<ul style="list-style-type: none"> <li>● Ranges from 0 (“normal sensation”) to 20 (“most severe sensory deficit”)</li> <li>● Sensory scale comprises pin prick and vibration sense plus a two point discrimination value in the arms and legs</li> </ul>

\*Studies demonstrate that the MRC sum score, hand grip strength measured by the Vigorimeter, and the INCAT sensory summary score demonstrate good clinimetric properties in individuals with immune mediated polyneuropathies (CIDP, GBS, etc.) The Rankin and modified Rankin are primarily used in stroke individuals.

## Appendix 5

### **American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM) Consensus Criteria for the Diagnosis of Multifocal Motor Neuropathy**

#### Criteria for **definite** multifocal motor neuropathy

- 1) Weakness without objective sensory loss in the distribution of two or more named nerves. During the early stages of symptomatic weakness, the historical or physical finding of diffuse, symmetric weakness excludes multifocal motor neuropathy.
- 2) Definite conduction block (see Table 1 of the complete reference) is present in two or more nerves outside of common entrapment sites.\*
- 3) Normal sensory nerve conduction velocity across the same segments with demonstrated motor conduction block.
- 4) Normal results for sensory nerve conduction studies on all tested nerves, with a minimum of three nerves tested. The absence of each of the following upper motor neuron signs: spastic tone, clonus, extensor plantar response, and pseudobulbar palsy.

#### Criteria for **probable** multifocal motor neuropathy

- 1) Weakness without objective sensory loss in the distribution of two or more named nerves. During the initial weeks of symptomatic weakness, the presence of diffuse, symmetric weakness excludes multifocal motor neuropathy.
- 2) The presence of either:
  - a. Probable conduction block in two or more motor nerve segments that are not common entrapment sites, or
  - b. Definite conduction block in one motor nerve segment and probable conduction block in a different motor nerve segment, neither of which segments are common entrapment sites.
- 3) Normal sensory nerve conduction velocity across the same segments with demonstrated motor conduction block, when this segment is technically feasible for study (that is, this is not required for segments proximal to axilla or popliteal fossa).
- 4) Normal results for sensory nerve conduction studies on all tested nerves, with a minimum of three nerves tested.
- 5) The absence of each of the following upper motor neuron signs: spastic tone, clonus, extensor plantar response, and pseudobulbar palsy.

\* *Median nerve at wrist; ulnar nerve at elbow or wrist; peroneal nerve at fibular head.* (Olney, 2003)

## **References**

1. Bivigam® 10% intravenous solution [prescribing information]. Boca Raton, FL: ADMA Biologics; March 2024.
2. Murrell D, Pena S, Joly P, et al. Diagnosis and management of pemphigus: Recommendations of an international panel of experts. *J Am Acad Dermatol.* 2020;82(3):575-585.
3. Flebogamma® 5% DIF intravenous solution [prescribing information]. Los Angeles, CA: Grifols; August 2024.

4. American College of Obstetricians and Gynecologists Practice Advisory. Management of obstetric-gynecologic patients during a measles outbreak. March 2024. Available at: [www.acog.com](http://www.acog.com). Accessed on 10/30/2024.
5. Gammagard® Liquid 10% solution [prescribing information]. Lexington, MA: Takeda; January 2024.
6. Gammagard® S/D IgA < 1 mcg/mL in a 5% intravenous solution [prescribing information]. Lexington, MA: Takeda; March 2023.
7. Gammaked™ 10% solution [prescribing information]. Fort Lee, NJ: Kedrion; January 2020.
8. Gammaplex® 5% intravenous solution [prescribing information]. Fort Lee, NJ: Kedrion; May 2024.
9. Gamunex®-C 10% solution [prescribing information]. Research Triangle Park, NJ: Grifols; January 2020.
10. Octagam® 5% intravenous solution [prescribing information]. Paramus, NJ: Octapharma; April 2022.
11. Octagam® 10% intravenous solution [prescribing information]. Paramus, NJ: Octapharma; April 2022.
12. Privigen® 10% intravenous solution [prescribing information]. Kankakee, IL: CSL Behring; March 2022.
13. McLean HQ, Fiebelkorn AP, Temte JL, Wallace GS; Centers for Disease Control and Prevention. Prevention of measles, rubella, congenital rubella syndrome, and mumps, 2013: summary recommendations of the Advisory Committee on Immunization Practices (ACIP). *MMWR Recomm Rep*. 2013;62:1-34.
14. Bonilla FA, Khan DA, Ballas ZK, et al. Practice parameter for the diagnosis and management of primary immunodeficiency. *J Allergy Clin Immunol*. 2015;136(5):1186-205.
15. Panzyga 10% intravenous solution [prescribing information]. New York, NY: Pfizer; February 2021.
16. Asceniv 10% intravenous solution [prescribing information]. Boca Raton, FL: ADMA Biologics; April 2019.
17. Bonilla FA, Barlan I, Chapel H, et al. International Consensus Document (ICON): Common variable immunodeficiency disorders. *J Allergy Clin Immunol Pract*. 2016;4(1):38-59.
18. Perez EE, Orange JS, Bonilla F, et al. Update on the use of immunoglobulin in human disease: A review of evidence. *J Allergy Clin Immunol*. 2017;139(3S):S1-S46.
19. Wasserman RL, Lumry W, Harris J, et al. Efficacy, safety, and pharmacokinetics of a new 10% liquid intravenous immunoglobulin containing high titer neutralizing antibody to RSV and other respiratory viruses in subjects with primary immunodeficiency disease. *J Clin Immunol*. 2016;36:590-599.
20. Otani S, Davis AK, Cantwell L, et al. Evolving experience of treating antibody-mediated rejection following lung transplantation. *Transpl Immunol*. 2014;31(2):75-80.
21. The NCCN Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Clinical Practice Guidelines in Oncology (version 1.2025 – October 1, 2024). © 2024 National Comprehensive Cancer Network. Available at: <http://www.nccn.org>. Accessed on October 17, 2024.
22. Anderson D, Ali K, Blanchette V, et al. Guidelines on the use of intravenous immune globulin for hematologic conditions. *Transfus Med Rev*. 2007;21(2 Suppl 1):s9-56.
23. Neunert C, Terrell DR, Arnold DM, et al. American Society of Hematology 2019 guidelines for immune thrombocytopenia. *Blood Adv*. 2019;3(23):3829-3866.
24. Neunert C, Lim W, Crowther M, et al. The American Society of Hematology 2011 evidenced-based practice guideline for immune thrombocytopenia. *Blood*. 2011;117:4190-4207.
25. Gammaplex 10% intravenous solution [prescribing information]. Fort Lee, NJ: Kedrion; May 2024.
26. American Academy of Pediatrics. Kawasaki disease. In: Kimberlin DW, Banerjee R, Barnett ED, , eds. Red Book; 2024 Report of the Committee on Infectious Diseases, 33<sup>rd</sup> Ed. American Academy of Pediatrics; 2024:522-529.
27. UK National Health Service. Commissioning position (2024). Clinical Commissioning Policy for the use of therapeutic immunoglobulin (Ig) England (2024). Accessed on October 17, 2024.
28. Ahmed AR. Use of intravenous immunoglobulin therapy in autoimmune blistering diseases. *Int Immunopharmacol*. 2006;6(4):557-578.
29. Enk A, Hadaschik E, Eming R, et al. European guidelines on the use of high-dose intravenous immunoglobulin in dermatology. *J Dtsch Dermatol Ges*. 2017;15(2):228-241.
30. Gurean HM, Jeph S, Ahmed AR. Intravenous immunoglobulin therapy in autoimmune mucocutaneous blistering diseases: a review of the evidence for its efficacy and safety. *Am J Clin Dermatol*. 2010;11:315-326.
31. The NCCN Prevention and Treatment of Cancer-Related Infections Clinical Practice Guidelines in Oncology (version 3.2024 – September 23, 2024). © 2024 National Comprehensive Cancer Network. Available at <http://www.nccn.org>. Accessed on October 17, 2024.
32. Glisson CC. UpToDate® 2024. Neuromyelitis optica spectrum disorder (NMOSD): Clinical features and diagnosis. Available at: [www.uptodate.com](http://www.uptodate.com). Accessed on October 30, 2024.

33. Aggarwal R, Charles-Schoeman C, Schessl J, et al. Prospective, double-blind, randomized, placebo-controlled, phase III study evaluating efficacy and safety of Octagam 10% in patients with dermatomyositis (ProDERM Study). *Medicine* (Baltimore). 2021;100(1):e23677.
34. Marfo K, Lu A, Ling M, Akalin E. Desensitization protocols and their outcome. *Clin J Am Soc Nephrol*. 2011;6:922-936.
35. Zachary AA, Leffell MS. Desensitization for solid organ and hematopoietic stem cell transplantation. *Immunol Rev*. 2014;258:183-207.
36. Colvin MM, Cook JL, Chang P, et al; American Heart Association Heart Failure and Transplantation Committee of the Council on Clinical Cardiology; American Heart Association Heart Failure and Transplantation Committee of the Council on Cardiopulmonary Critical Care, Perioperative and Resuscitation, et al. Antibody-mediated rejection in cardiac transplantation emerging knowledge in diagnosis and management: a scientific statement from the American Heart Association. *Circulation*. 2015;131:1608-1639.
37. Hughes RA, Wijdicks, EF, Barohn R, et al. Quality Standards Subcommittee of the American Academy of Neurology. Practice parameter: immunotherapy for Guillain-Barre syndrome: report of the Quality Standards Subcommittee of the American Academy of Neurology. *Neurology*. 2003;61:736-740. Guideline Reaffirmed January 22, 2022.
38. Van Doorn PA, Van den Bergh PYK, Hadden RDM, et al. European Academy of Neurology/Peripheral Nerve Society guideline on diagnosis and treatment of Guillain-Barre syndrome. *Eur J Neurol*. 2023;30(12):3646-3674.
39. Tomblyn M, Chiller T, Einsele H, et al; Center for International Blood and Marrow Research; National Marrow Donor program; European Blood and Marrow Transplant Group; American Society of Blood and Marrow Transplantation; Canadian Blood and Marrow Transplant Group; Infectious Diseases Society of America; Society for Healthcare Epidemiology of America; Association of Medical Microbiology and Infectious Disease Canada; Centers for Disease Control and Prevention. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: A global perspective. *Biol Blood Marrow Transplant*. 2009;1:1143-1238.
40. Panel on Opportunistic Infections in Children with and Exposed to HIV. Guidelines for the prevention and treatment of opportunistic infections in children with and exposed to HIV. Department of Health and Human Services. Last review July 3, 2024. Available at: Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Exposed and HIV-Infected Children. Accessed on October 17, 2024.
41. American Academy of Pediatrics. Human Immunodeficiency Virus Infection. In: Kimberlin DW, Banerjee R, Barnett ED, eds. *Red Book®: 2024 Report of the Committee on Infectious Diseases, 33<sup>rd</sup> Ed.* American Academy of Pediatrics; 2024:489-503.
42. The NCCN Multiple Myeloma Clinical Practice Guidelines in Oncology (version 1.2025 – September 17, 2024). © 2024 National Comprehensive Cancer Network. Available at <http://www.nccn.org>. Accessed on October 17, 2024.
43. National Multiple Sclerosis Society. Relapse management. Available at: <http://www.nationalmssociety.org/For-Professionals/Clinical-Care/Managing-MS/Relapse-Management>. Accessed on October 17, 2024.
44. Hachem RR, Yusen RD, Meyers BF, et al. Anti-human leukocyte antigen antibodies and preemptive antibody-directed therapy after lung transplantation. *J Heart Lung Transplant*. 2010;29:973.
45. Lejeune A, Martin L, Santibanez S, et al. Postexposure prophylaxis with intravenous immunoglobulin G prevents infants from getting measles. *Acta Paediatr*. 2017;1066(1):174-177.
46. American Academy of Pediatrics. Varicella-Zoster Infections. In: Kimberlin DW, Banerjee R, Barnett ED, eds. *Red Book®: 2024 Report of the Committee on Infectious Diseases, 33<sup>rd</sup> Ed.* American Academy of Pediatrics; 2024:938-951.
47. VariZIG® for intramuscular injection [prescribing information]. Roswell, GA: Saol Therapeutics; September 2021.
48. Centers for Disease Control and Prevention. Tetanus. Available at: Clinical Care of Tetanus | Tetanus | CDC. Accessed on October 17, 2024.
49. Broliden K, Tolfyenstam T, Norbeck O. Clinical aspects of parvovirus B19 infection. *J Intern Med*. 2006;260:285-304.
50. Symington A, Paes B. Fetal and neonatal alloimmune thrombocytopenia: harvesting the evidence to develop a clinical approach to management. *Am J Perinatal*. 2011;28:137-144.
51. Townsley DM. Hematologic complications of pregnancy. *Semin Hematol*. 2013;50:222-231.

52. Kumpfel T, Giglhuber K, Aktas O, et al. Update on the diagnosis and treatment of neuromyelitis optica spectrum disorders (NMOSD) – revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part II: Attack therapy and long-term management. *J Neurol*. 2024;271:141-176.
53. Yimmugo® 10% intravenous solution [prescribing information]. Dreieich, Germany. Biotest (Grifols); June 2024.
54. From the Global Strategy for Asthma Management and Prevention, Global Initiative for Asthma (GINA) 2024. Available at: <https://ginasthma.org/>. Accessed on October 17, 2024.
55. Eichenfield LF, Ahluwalia J, Waldman A, et al. Current guidelines for the evaluation and management of atopic dermatitis: A comparison of the Joint Task Force Practice Parameter and American Academy of Dermatology Guidelines. *J Allergy Clin Immunol*. 2017;139(4S):S49-S57.
56. Allenbach Y, Mammen AL, Benveniste O, et al. 224<sup>th</sup> ENMC International Workshop: Clinico-seropathological classification of immune-mediated necrotizing myopathies. Zandvoort, The Netherlands, 14-16 October 2016. *Neuromuscul Disord*. 2018;28(1):87-99.
57. Goebel A, Baranowski A, Maurer K, et al. Intravenous immunoglobulin treatment of the complex regional pain syndrome: A randomized trial. *Ann Intern Med*. 2010;152:152-158.
58. Goebel A, Bisla J, Carganillo R, et al. Low-dose intravenous immunoglobulin treatment for long-standing complex regional pain syndrome: A randomized trial. *Ann Intern Med*. 2017;167(7):476-483.
59. Chrissafidou A, Malek M, Musch E. Experimental study on the use of intravenous immunoglobulin in patients with steroid-resistant Crohn's disease. *Gastroenterol*. 2007;45:605-608.
60. Balfour-Lynn IM, Mohan U, Bush A, Rosenthal M. Intravenous immunoglobulin for cystic fibrosis lung disease: a case series of 16 children. *Arch Dis Child*. 2004;89:315-319.
61. Relkin NR, Thomas RG, Rissman RA, et al. A phase 3 trial of IV immunoglobulin for Alzheimer disease. *Neurology*. 2017;88(18):1768-1775.
62. Christopher-Stine L. UpToDate® 2024. Clinical manifestations and diagnosis of immune-mediated necrotizing myopathy and Treatment of immune-mediated necrotizing myopathy. Available at: [www.uptodate.com](http://www.uptodate.com). Accessed on October 30, 2024.
63. Tavee J, Brannagan TH, Lenihan MW, et al. Updated consensus statement: Intravenous immunoglobulin in the treatment of neuromuscular disorders report of the AANEM ad hoc committee. *Muscle Nerve*. 2023;68(4):356-374.
64. Caro XJ, Winter EF, Dumas AJ. A subset of fibromyalgia patients have findings suggestive of chronic inflammatory demyelinating polyneuropathy and appear to respond to IVIG. *Rheumatology (Oxford)*. 2008;47:208-211.
65. Sanders DB, Wolfe GI, Benatar M, et al. International consensus guidance for management of myasthenia gravis: Executive summary. *Neurology*. 2016;87(4):419-425.
66. Eid AJ, Ardura MI, AST Infectious Disease Community of Practice. Human parvovirus B19 in solid organ transplantation: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. *Clin Transplant*. 2019 Sep;33(9):e13535.
67. Van den Bergh PY, van Doorn PA, Hadden RD, et al. European Academy of Neurology/Peripheral Nerve Society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: Report of a joint Task Force – Second revision. *J Peripher Nerv Syst*. 2021 Sep;26(3):242-268.
68. Practice Committee of the American Society for Reproductive Medicine. The role of immunotherapy in in vitro fertilization: a guideline. *Fertil Steril*. 2018;110:387-400.
69. Banwell B, Bennett JL, Marignier R, et al. Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: International MOGAD Panel proposed criteria. *Lancet Neurol*. 2023;22:268-282.
70. Sechi E, Cacciaguerra L, Chen JJ, et al. Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD): A review of clinical and MRI features, diagnosis, and management. *Front Neurol*. 2022;13:885218.
71. Mcheik S, Peramo B, Quenby S, et al. ESHRE guideline: recurrent pregnancy loss: an update in 2022. *Hum Reprod Open*. 2023(1):hoad002. doi: 10.1093/hropen/hoad002.
72. The Practice Committee of the American Society for Reproductive Medicine. Evaluation and treatment of recurrent pregnancy loss: a committee opinion. *Fertil Steril*. 2012;95:1103-1111.
73. The NCCN Management of Immunotherapy-Related Toxicities Clinical Practice Guidelines in Oncology (version 2.2024 – October 25, 2024). © 2024 National Comprehensive Cancer Network. Available at: <http://www.nccn.org>. Accessed on November 12, 2024.

74. Schneider BJ, Naidoo J, Santomaso BD, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology guideline update. *J Clin Oncol.* 2021;39(36):4073--4126.
75. Garces JC, Biusti S, Giusti S, et al. Antibody-mediated rejection: A review. *Ochsner J.* 2017;17(1):46-55.
76. Wan SS, Yin TD, Wyburn K, et al. The treatment of antibody-mediated rejection in kidney transplantation: An updated systematic review and meta-analysis. *Transplantation.* 2018;102(4):557-568.
77. Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group. KDIGO clinical practice guideline for the care of kidney transplant recipients. *Am J Transplant.* 2009;9(Suppl 3):S1.
78. Witt CA, Gaut JP, Yusen RD, et al. Acute antibody-mediated rejection after lung transplantation. *J Heart Lung Transplant.* 2013;32:1034.
79. Ma Y, Man J, Niu J, et al. Progress of research on human parovirus B19 infection after renal transplantation. *Transplant Rev.* 2022;36(4):100730.
80. Alyglo™ 10% intravenous solution [prescribing information]. Teaneck, NJ: GC Biopharma; December 2023.

## Revision Details

Type of Revision	Summary of Changes	Date
Annual Revision	<p>No criteria changes</p> <p><b>HCPs Coding Information.</b>  <b>Removed</b> J1599  <b>Added</b> J1552 (effective date 1/1/2024)</p> <p><b>ICD-10-CM Coding Information.</b>  <b>Added</b> T45.AX5A, T45.AX5D, T45.AX5 (effective date 10/1/2024)</p>	02/01/2025
Selected Revision	<p><b>Multiple Myeloma.</b>  <b>Updated</b> criteria for use in recurrent infection  <b>Added</b> the following option for approval in initial therapy as an alternative to infection status 1) Patient will be starting, has taken, or is currently receiving chimeric antigen receptor (CAR)-T cell therapy OR bispecific antibody therapy. Note: Examples of CAR-T cell therapy includes: Abecma (idecabtagene vicleucel intravenous infusion), Carvykti (ciltacabtagene autoleucel intravenous infusion). Note: Examples of bispecific antibody therapy includes: Elrexfio (elranatamab-bcmm subcutaneous injection), Tecvayli (teclistamab-cqyv subcutaneous injection), Talvey (talquetamab-tgvs subcutaneous injection).</p>	07/01/2025
Selected Revision	<p><b>Conditions Not Covered.</b>  <b>Updated</b> “experimental, investigational, or unproven” to “not medically necessary”</p>	10/1/2025
Selected Revision	<p><b>Removed</b> preferred product requirements for HyQvia.  <b>Updated</b> preferred product requirements for Gammagard Liquid.</p>	11/01/2025
Selected Revision	<p><b>Employer Plans and Individual and Family Plans Preferred Product Table:</b>  <b>Gammagard Liquid: removed</b> preferred product requirements for Gammagard Liquid</p>	03/01/2026

	<b>Gammagard S/D IgA ≤ 1 mcg/mL: updated</b> criteria for the exception of “Patient requires an IVIG product with the lowest IgA content”	
Selected Revision	<p><b>Added</b> Yimmugo® to the policy along with preferred product criteria for Employer Plans and Individual and Family Plans.</p> <p><b>Coding Information:</b></p> <ul style="list-style-type: none"> <li>• <b>Removed</b> HCPCS E0779 &amp; E0781</li> <li>• <b>Added</b> HCPCS J1553 with an effective date of 4/1/2026.</li> <li>• <b>Removed</b> the effective date of 1/1/2025 from HCPCS J1552.</li> </ul>	4/1/2026

The policy effective date is in force until updated or retired.

---

“Cigna Companies” refers to operating subsidiaries of The Cigna Group. All products and services are provided exclusively by or through such operating subsidiaries, including Cigna Health and Life Insurance Company, Connecticut General Life Insurance Company, Evernorth Behavioral Health, Inc., Cigna Health Management, Inc., and HMO or service company subsidiaries of The Cigna Group. © 2026 The Cigna Group.